ENDP up +1.27% percent Today $ENDP High is at 67.08 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
ENDP up +1.27% percent Today $ENDP High is at 67.08 and the Low 66.13 with current volume of 119,992.

Recent News posted below.

Endo Pharmaceuticals Holdings Inc ENDP other info.
http://investorshangout.com/Endo-Health-Solut...NDP-54014/

ENDP Endo Pharmaceuticals Holdings Inc Recent Headline News

After Yesterday's Decline of 1.25%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 4:38PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.00 to a high of $68.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $66.94 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 66.72 (+0.46)

Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 66.72 (+0.46), ACT: 249.80 (+6.03), JAZZ: 171.30 (-3.27), UNH: 96.09 (+0.98), CELG: 104.54 (+0.49), CELGZ: 3.28 (unch)

La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 66.72 (+0.46), LCI: 47.45 (+0.57), BCRX: 10.17 (+0.10), LJPC: 11.29 (+0.23)

Endo Receives Final Approval for Generic Version of Valcyte®
PR Newswire - Mon Nov 10, 7:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Qualitest subsidiary has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg).
ENDP: 66.72 (+0.46), ENL.TO: 74.77 (-0.38)

Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST

ENDP: 66.72 (+0.46), AUXL: 32.24 (+0.07)

Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST

ENDP: 66.72 (+0.46), RDY: 55.94 (-0.09)

Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 210.46 (+11.81), ENDP: 66.71 (+0.45), AUXL: 32.24 (+0.07), ABBV: 65.29 (+1.29)

Endo International's (ENDP) CEO Rajiv Kanishka Liyanaarchchie De Silva on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:50PM CST

ENDP: 66.71 (+0.45)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.45 (+0.55), ENDP: 66.71 (+0.45), AUXL: 32.24 (+0.07), SHPG: 204.81 (+2.19), DNDN: 0.16 (+0.05), SNSS: 2.50 (+0.83), ABBV: 65.29 (+1.29), SNY: 47.39 (+0.71), MNKD: 6.14 (-0.02), XOMA: 3.97 (+0.05)

Endo International (ENDP) Is Today's Water-Logged And Getting Wetter Stock
at The Street - Wed Nov 05, 9:29AM CST
Trade-Ideas LLC identified Endo International (ENDP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ENDP: 66.71 (+0.45)

Endo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:18AM CST

ENDP: 66.71 (+0.45)

Endo International (ENDP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:55AM CST

ENDP: 66.71 (+0.45)

Endo beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:09AM CST

ENDP: 66.71 (+0.45)

Endo Reports Third Quarter Financial Results
PR Newswire - Wed Nov 05, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported third quarter 2014 revenues of $764 million, an increase of 16 percent compared to third quarter 2013 revenues of $661 million. Endo reported a net loss of $252 million in the third quarter 2014 compared to net income of $40 million in the third quarter of 2013.
ENDP: 66.71 (+0.45), ENL.TO: 74.77 (-0.38)

Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST

MDLZ: 38.20 (+0.04), CSTE: 59.51 (+0.14), FSS: 15.67 (+0.02), HL: 2.46 (-0.06), BBEP: 15.12 (-0.43), RRD: 16.90 (-0.03), CNP: 24.16 (+0.12), INXN: 28.26 (-0.02), OGE: 36.53 (+0.18), MNTA: 10.63 (unch), GLDD: 7.05 (-0.18), AXAS: 3.89 (-0.18), MEMP: 16.13 (-0.24), PWE: 4.16 (-0.06), ROC: 79.15 (-0.04), SSYS: 104.67 (-0.18), DNR: 9.93 (-1.27), MVIS: 1.70 (unch), PWR: 33.09 (-0.07), COV: 94.39 (+0.41), SMG: 59.94 (-0.66), SEP: 56.90 (+0.54), CLH: 49.80 (+0.85), ATHM: 42.88 (-1.70), STWD: 23.46 (-0.06), BPI: 10.96 (-0.30), LVLT: 48.73 (-0.31), AVA: 33.70 (+0.24), MGA: 104.19 (+0.27), BSFT: 27.42 (-0.08), EE: 37.89 (+0.34), CTSH: 53.03 (-0.25), DAVE: 25.69 (-0.06), NRG: 31.22 (-0.09), CEQP: 8.37 (-0.09), ACT: 249.80 (+6.03), AWR: 34.52 (+0.28), DUK: 80.05 (+0.94), LAMR: 52.77 (+0.22), CCC: 21.06 (-0.16), HFC: 43.18 (+0.35), RTI: 23.45 (-0.17), CHK: 23.03 (-0.18), NUS: 39.26 (-0.14), NICE: 46.40 (-0.02), HRC: 45.04 (+0.28), ENDP: 66.71 (+0.45), SE: 38.44 (+0.32), CBB: 3.41 (-0.06), GTN: 10.20 (+0.09), ANSS: 79.94 (+0.15), RLGY: 42.73 (-0.24), ENB: 45.26 (-0.11), SBGI: 27.96 (-0.13), ARIA: 6.05 (-0.10), LPX: 14.61 (unch), RDC: 23.43 (-0.32), KELYA: 15.12 (-0.30)

Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 43.88 (+0.74), ENDP: 66.71 (+0.45), VRX: 134.94 (+0.73), PFE: 30.01 (-0.33)

Endo reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:03PM CDT

ENDP: 66.71 (+0.45)

3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.71 (+0.45), VRX: 134.94 (+0.73), ACT: 249.80 (+6.03), AMGN: 158.68 (+1.00), TKMR: 17.09 (+0.68), GSK: 45.84 (+0.10), AGN: 210.48 (+11.83), JNJ: 108.31 (+0.15), SHPG: 204.81 (+2.19), MRK: 59.62 (+0.55), INFI: 14.25 (+0.15), ABBV: 65.29 (+1.29), KPTI: 40.49 (+0.72)

Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 66.71 (+0.45), PRGO: 154.09 (-0.37), AUXL: 32.24 (+0.07), DEPO: 15.23 (+0.23), AMPE: 3.32 (-0.02)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Abbott's Oncodetect Test: Game-Changer for Cancer Recurrence

Updated Category News Views 3

Pioneering Progress in Colorectal Cancer Detection There's a new player in the world of cancer diagnostics, and it's setting a fresh standard. Abbott's Oncodetect test, featured at the ESMO Congress, has shown a profound leap in sensitivity—30 percent over the older whole-exome sequencing approach. For those doing the math on the stock charts, Abbott (NYSE: ABT) is...

Continue Reading
Gala Spotlights Veterans' Mental Health Support

Updated Category News Views 8

Champions for Veterans Honored at Headstrong Gala If you ever wondered who stands in the trenches alongside veterans facing mental health battles, this year's Headstrong Gala offered a crystal-clear answer. Held on October 16 at Pier Sixty in New York City, this shiindig wasn’t just about schmoozing over canapés. It was about celebrating the grit and guts of those...

Continue Reading
Navigating Home Sales: Expert Insights from Jodi Kallus

Updated Category News Views 1

Preparing for the Real Estate Rollercoaster Getting ready to sell your home? Let's cut through the noise and get right into the nitty-gritty with Jodi Kallus, a seasoned real estate pro with Summit Realtors. The first step ain't just about slapping a ‘For Sale’ sign on your front lawn. It's about laying down a plan that's as solid as the foundation of the house you're...

Continue Reading
Infosys Pushes AI Growth with Strong Deal Wins

Updated Category News Views 3

Riding the AI Wave Who knew Infosys was a lightning rod for AI momentum, eh? With a 29% quarterly surge in AI revenue, the firm's really putting AI strategy at center stage. Considering today's finicky markets, that's not just peanuts. CEO Salil Parekh's swagger is backed by real numbers, seeing AI revenue inch to 10.5% of total haul. This ain't just talk—Infosys is...

Continue Reading
Ping An Good Doctor Grows 35%: AI's Expanding Role

Updated Category News Views 5

Ping An Good Doctor's Noteworthy Financial Uptick Stop me if you've heard this one: a hefty hike in numbers that make investors straighten up a bit. Ping An Good Doctor did just that, reporting a 35% spark in net profit as the books closed up till September 2026. In a landscape where many health-tech firms merely tread water, these guys rode a wave of RMB 0.25 billion in...

Continue Reading
Palmstreet Amplifies Designer Toys at Las Vegas Con

Updated Category News Views 9

Designer Toys Take the Spotlight Palmstreet's latest move into the designer toy world is buzzing with anticipation. This live-shopping app, initially catering to rare plants, is taking its evolution seriously with another plunge into exclusive collectibles, this time showcasing unique collaborations at DesignerCon in Las Vegas. While Palmstreet may have started in a...

Continue Reading
Lincoln Educational Faces Investor Lawsuit Over Revenue Drop

Updated Category News Views 3

Investors Face Rough Waters Okay, let’s dive into this latest mess at Lincoln Educational Services Corp. (NASDAQ:LINC). Things aren't smelling too rosy over at their headquarters. If you've got shares here, you’ll know what I mean. Back in early May, the folks running Lincoln threw a garden party talking up a 19.5% growth in student starts. Who wouldn’t get behind...

Continue Reading
Unicoin’s 'RISE IN PINK' Blends Crypto and Charity

Updated Category News Views 1

The New Face of Charitable Giving: Crypto and Cause Turning the spotlight on how blockchain and altruism can mesh, Unicoin's latest campaign isn’t just your average philanthropic endeavor. With 'RISE IN PINK', they're out to change the game, blending digital assets with a deep human cause—breast cancer awareness and support. Technology Meets Human Cause Imagine...

Continue Reading
S&P Global's New Dashboard: Unpacking Data Insights

Updated Category News Views 3

An Interactive Take on Digital Infrastructure The geniuses over at S&P Global Ratings have just unleashed a shiny new tool for number crunchers and market hawks who can't get enough data center action—an interactive dashboard. Maybe not everyone’s cup of tea, but hey, in the dog-eat-dog world of digital infrastructure, any edge counts. What's in the Data Center Soup?...

Continue Reading
Patrick Ta Beauty Adds New Leadership to Expand Growth

Updated Category News Views 2

Angela Simpson and Carolyne Rapp Join the Ranks In the fast-paced world of beauty, where trends shift faster than a day trader’s mood, Patrick Ta Beauty is shaking things up with some heavyweight hires. Angela Simpson steps in as Chief Marketing Officer, and Carolyne Rapp takes the reins as Vice President of Creative. Maybe it’s just me, but when a brand ropes in pros...

Continue Reading

Top 5 Most Recently Viewed Articles

JMGO's O2S Ultra 4K Projector Revolutionizes Home Cinema Experience

Updated Category News Views 175

JMGO Announces the Innovative O2S Ultra 4K Tri-Laser TV Projector JMGO, a leader in optical technology, has unveiled its latest innovation, the O2S Ultra 4K Tri-Laser TV projector. This announcement occurred at a prominent technology event, showcasing JMGO's dedication to advancing home entertainment technology. Transforming Home Viewing with the O2S Ultra 4K The O2S...

Continue Reading
Faircourt Gold Income Corp. Reveals Class A Share Redemption Details

Updated Category News Views 340

Key Details of Faircourt Gold Income Corp.’s Redemption Process Faircourt Asset Management Inc., managing Faircourt Gold Income Corp., has exciting updates for securityholders. For those who opted to redeem their Class A Shares, the net asset value per share is set at $3.9552. This value reflects a calculated average price from the last five trading days, showcasing the...

Continue Reading
BrightSpire Capital's Upcoming Earnings Call and 2024 Results Insight

Updated Category News Views 94

BrightSpire Capital to Release Fourth Quarter Financial Results BrightSpire Capital, Inc. (NYSE: BRSP) has announced an important event for its investors. The company is set to disclose its fourth quarter and full year 2024 financial results on a specified date in February, following the close of the market. This is an exciting time for shareholders, as financial releases...

Continue Reading
Partners Value Split Corp. Expands Preferred Shares Offering to $200M

Updated Category News Views 267

Partners Value Split Corp. Expands Preferred Shares Offering In a significant move reflecting robust investor interest, Partners Value Split Corp. has announced an increase in the public offering of its Class AA Preferred Shares, Series 15. The offering is now set at a remarkable $200 million, showcasing the confidence engendered among investors. Details of the Offering...

Continue Reading
Palvella Therapeutics Advances QTORIN™ Gel for Rare Skin Disorders

Updated Category News Views 166

Palvella's QTORIN™ Gel Unveiled at Pediatric Dermatology Congress In an exciting development for patients suffering from microcystic lymphatic malformations (microcystic LMs), Palvella Therapeutics has announced the presentation of its QTORIN™ rapamycin 3.9% anhydrous gel. This groundbreaking product was featured by Dr. Amy Paller during an oral presentation at a...

Continue Reading